Novo Nordisk announced a strategic partnership with OpenAI on April 14, 2026, to integrate AI into drug research and development.12
The collaboration will use AI to analyze complex datasets, identify promising drug candidates, and reduce time from research to patient delivery.123
AI will also enhance efficiency in manufacturing, supply chain, distribution, and corporate operations, with pilot programs starting now and full integration by end of 2026.12
The partnership includes strict data protection, governance, human oversight, and OpenAI-assisted upskilling of Novo Nordisk's workforce.12
Novo Nordisk's CEO Mike Doustdar stated this positions the company to lead in healthcare innovation for obesity and diabetes treatments.12
OpenAI CEO Sam Altman highlighted AI's role in accelerating scientific discovery and improving patient care.2
Sources:
1. https://www.computerweekly.com/news/366641591/Novo-Nordisk-partners-with-OpenAI-to-AI-power-drug-development
2. https://www.investing.com/news/company-news/novo-nordisk-partners-with-openai-to-speed-up-drug-discovery-4611897
3. https://www.pharmaceutical-technology.com/news/novo-nordisk-openai-drug-development-partnership/